Navigation Links
Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients
Date:7/13/2011

X001 will be able to make a significant difference."

"We believe CMX001's rapidly evolving antiviral and safety profile provides strong support for this candidate's broad-spectrum, preemptive usage, which includes the often-overlooked pediatric population," said Kenneth I. Moch, Chimerix President and CEO. "To date, CMX001 has been administered to more than 550 subjects and has demonstrated activity against a broad spectrum of dsDNA viruses.  It has been well tolerated and has not shown toxicity in the kidneys or on bone marrow function."  

The AdV HALT Trial/CMX001-202 Design

The primary objective of the Phase 2 clinical study is to evaluate the safety and efficacy of preemptive treatment with CMX001 versus placebo for the prevention of AdV disease in hematopoietic stem cell recipients with asymptomatic AdV viremia.  The multi-center, placebo-controlled study, which will be conducted at approximately 30 centers, is expected to enroll 48 pediatric and adult patients who have undergone hematopoietic stem cell transplant and have evidence of infection but no symptoms of disease.  Under the protocol, subjects will be randomized to receive CMX001 or placebo once or twice weekly for at least six, but no more than 12, weeks. The dose of CMX001 or placebo given during the randomized treatment phase will be based upon the age and weight of the subject at the time of enrollment.

The primary endpoint will be "treatment failure", consisting of progression to AdV disease or increasing AdV viremia. Secondary endpoints include safety and tolerability of CMX001, as well as other measurements that include the percentage of subjects who have emergence or progression of cytomegalovirus(CMV), Epstein-Barr virus (EBV), or BK virus (BKV) viremia or disease during therapy.  Drug pharmacokinetics and the development of viral resistance will also be assessed.  

Additional information on study objectives, enrollment cri
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
2. Chimerix Joins International Network of Organizations to Cure Malaria
3. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
4. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
5. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
6. Chimerix Initiates Phase 1 Study of CMX157
7. Chimerix to Present at Upcoming Investor Conferences
8. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
9. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
10. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
11. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... results of a new study led by George ... evidence that nucleation of ice in small droplets ... water,s behavior at the nanoscale. The formation of ... scientific research question whose answer also has important ... , The crystallization of ice from supercooled water ...
(Date:5/21/2013)... The congress of the ERA-EDTA (European Renal Association ... congress in Europe on nephrology ... Istanbul to share their knowledge ... have been presented: / (1) Gupta, A ... REDUCES ESA USE" By SFP-iron administration, the ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 ... services company for clinical trials, announced today it ... Solutions, LLC. Clinverse’s ClinPay® FLS eClinical commerce ... payment process. SpendMD ™, Aggregate Spend ... solution for tracking and reporting transfer of value ...
(Date:5/21/2013)... ALBANY, New York , May 21, 2013 /PRNewswire/ ... published by Transparency Market Research ( http://www.transparencymarketresearch.com ) "Biochip ... Science Research, IVD Tests) - U.S. Industry Analysis, Size, Share, ... USD 2.4 billion in 2011 and is expected to ... 2018, to reach an estimated value of USD 4.7 ...
Breaking Biology Technology:Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5
... Nets to Prevent Serious Health Hazards ... Associated with Diethylene ... Pharmacopeial (USP),Convention today announced a revised Glycerin monograph in ... United States. The,revision strengthens safety nets to prevent serious ...
... The following was issued,today by the Greater Baltimore ... CEO, Greater Baltimore Committee, 140 company owners, executives ... The third annual Greater Baltimore Region Bioscience Awards, ... / Breakfast & Registration, 8:45 - 9:30 a.m. ...
... March 17 Mercury Therapeutics,Inc. (MTI), a ... protein,kinase targeted drugs, announces that it has ... advise on its strategic and partnering,opportunities, with ... shareholders., This appointment follows a significant ...
Cached Biology Technology:USP Announces Revised Glycerin Monograph 2USP Announces Revised Glycerin Monograph 3Greater Baltimore Committee to Announce Winners of Third Baltimore Region Bioscience Awards at Ceremonies on March 18 2Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities 2Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities 3
(Date:5/21/2013)... MA -- Over the past few decades, scientists have ... angioplasty balloons and metallic stents. While generally effective, each ... side effects. , A new study from MIT analyzes ... the benefits of angioplasty balloons and drug-releasing stents, but ... balloon is inflated in the artery for only a ...
(Date:5/20/2013)... are also commonly resistant to antimicrobial substances made ... in mBio , the online open-access journal ... colistin and host antimicrobials LL-37 and lysozyme, which ... mean that patients with life-threatening multi-drug resistant infections ... Colistin is a last-line drug for treating several ...
(Date:5/20/2013)... (NSF) planning grant will help establish the Center for ... the University of Illinois at Urbana-Champaign and Worcester Polytechnic ... devoted to research in drying moist, porous materials such ... products; chemical products; textiles; and biopharmaceuticals," said Hao Feng, ... human nutrition and the Illinois site director. , According ...
Breaking Biology News(10 mins):Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3NSF approves planning grant for Center for Advanced Research in Drying 2
... forest loss accounts for an estimated 17% of global ... to reduce these greenhouse gas fluxes to the atmosphere, ... is working to adopt a strategy for Reducing Emissions ... climate treaty. For tropical nations to be effective ...
... keeping a secret that may be the key to defeating ... at Rice University and Baylor College of Medicine (BCM) have ... for evading detection by the immune system. Comparing its ... first known appearance in the deadly "Spanish flu" outbreak of ...
... (Dec. 10, 2009) -- One of the promises of nanomedicine ... on diseased cells and get inside them. Nanoparticles can carry ... diagnostic tests; and they may eventually even enter a cell,s ... much luck as engineering. "Everything in nanomedicine right now ...
Cached Biology News:First phase of pan-tropical forest mapping debuting at COP15 2First phase of pan-tropical forest mapping debuting at COP15 3Study reveals H1N1 unexpected weakness 2Nanomedicine: Ending 'hit and miss' design 2Nanomedicine: Ending 'hit and miss' design 3
Mouse monoclonal antibody raised against a partial recombinant ARHGEF11. NCBI Entrez Gene ID = ARHGEF11...
Mouse monoclonal antibody raised against a partial recombinant MYO7A. NCBI Entrez Gene ID = MYO7A...
... ,High Quality, Functionally-Validated, Ion Channel Cell Lines ... having a critical role in nerve and ... function in pain, CNS and the heart. ... investigated in therapeutic areas, such as neuropathic ...
... PrecisION Ion Channel Cell Lines ,High Quality, ... channels are well known for having a ... and consequently have a key function in ... modulate ion channels have been investigated in ...
Biology Products: